



# CPT® Editorial Summary of Panel Actions

May 2023

## CPT® Editorial Summary of Panel Actions May 2023

Please be aware that these actions are a reflection of the discussions at the most recent Panel meeting. Disclosure of Panel action and deliberation is limited to the information contained in this Summary of Actions. Premature release of coding information other than that contained in this document is prohibited under the [CPT Confidentiality Agreement](#). Codes are not assigned, nor exact wording finalized, until just prior to publication. Release of more specific CPT® code set information is timed with the release of the entire set of coding changes in the CPT publication.

If an applicant or other interested party believes an action of the CPT Editorial Panel was in error, that individual or entity may request reconsideration of the Panel action. An “interested party” is an individual or entity that may potentially be impacted by the Panel’s decision, regardless of whether they participated in the Panel’s original consideration of the matter.

**Submitting the Request:** Requests for reconsideration must be received by AMA staff no later than midnight, Central, June 16, 2023, fourteen (14) days after the published posting date (June 2, 2023) of the Summary Grid of Editorial Panel Actions on the CPT website <https://www.ama-assn.org/about/cpt-editorial-panel/summary-panel-actions>. The request should contain (1) the specific action requested for reconsideration; (2) the basis for the reconsideration request; and (3) all information relevant to the matter, including any literature (whether favorable or adverse) related to the requestor’s position. Requests for reconsideration and relevant information must be in writing and submitted (via email) to:

**Zach Hochstetler**  
Director, CPT Coding & Regulatory Affairs  
American Medical Association  
[Zachary.hochstetler@ama-assn.org](mailto:Zachary.hochstetler@ama-assn.org)

**Participation by Interested Parties:** The receipt of a request for reconsideration, the identity of the party seeking such, and a summary of the basis for the reconsideration request will be noted in the summary grid of Editorial Panel actions for the agenda item. The applicant and interested parties are responsible for monitoring postings to the CPT website with respect to requests for reconsideration. CPT staff will make reasonable efforts to identify potentially interested parties and notify them of the receipt of the request for reconsideration and the opportunity to be heard. An interested party seeking to comment on the request for reconsideration should submit its comments within fourteen (14) days of the posting of the notice (see deadline in **Submitting the Request** above) in the summary grid of Editorial Panel actions that a request for reconsideration has been received. Comments should include (i) a statement of the nature of the commenter’s interest in the issue, (ii) the specific comment and reason for the comment, and (iii) all relevant material including any literature (whether favorable or adverse) related to the commenter’s position. Comments should be submitted to the Director of CPT Coding & Regulatory Affairs at the address shown above. The applicant(s) who submitted the original code change proposal is automatically considered an interested party and will receive notice of any request for reconsideration submitted by another party.

Note: Codes that contain an 'X' (e.g., 102X4, 234X2, 030XT) are placeholder codes that are intended, through the first three digits, to give readers an idea of the proposed placement in the code set of the potential code changes. These codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed around early to mid-September of each year. To report the services for 'X' codes, please refer to the actual codes as they appear in the CPT Datafiles publication.

Updated June 1, 2023

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

| Tab # | Name   | Code #   | Request-Description  | Effective Date |
|-------|--|--|--|----------------|
| 6     | Critical Care Services                                     | -----  | <b>WITHDRAWN</b>   |                |
| 7     | E/M Guidelines Revision - Definition of Discussion         | -----  | <b>WITHDRAWN</b>   |                |
| 8     | Cat III to Cat I - Health and Well-being Coaching Services | -----  | <b>REJECTED</b>  |                |
| 9     | E/M Guideline Revisions - MDM Table                        | -----  | <b>WITHDRAWN</b>   |                |
| 10    | Cat III 0537T to Cat I - CAR-T Cell Therapy Services       | <ul style="list-style-type: none"> <li>● 3X018    D0537T</li> <li>● 3X019    D0538T</li> <li>● 3X020    D0539T</li> <li>● 3X021    D0540T</li> </ul>                                   | <b>Accepted addition</b> of codes 3X018 - 3X021 and guidelines to report Chimeric Antigen Receptor T Cell (CAR-T) Services; and <b>deletion</b> Category III codes 0537T - 0540T   | January 2025   |
| 11    | Nerve Block by Continuous Infusion                         | -----  | <b>WITHDRAWN</b>   |                |
| 12    | Intra-Abdominal Tumor Excision or Destruction              | <ul style="list-style-type: none"> <li>● 4X015    D49203</li> <li>● 4X016    D49204</li> <li>● 4X017    D49205</li> <li>● 4X018    D58957</li> <li>● 4X019</li> <li>▲ 58958</li> </ul> | <b>Accepted addition</b> of codes 4X015 - 4X019 (open procedure) to report excision, destruction, of intra-abdominal peritoneal, mesenteric, and/or retroperitoneal primary or secondary tumor(s), cyst(s); <b>revision</b> of code 58958; and <b>deletion</b> of codes 49203, 49204, 49205, 58957 | January 2025   |
| 13    | MRI-Monitored Transurethral US Ablation Prostate           | <ul style="list-style-type: none"> <li>● 5X006</li> <li>● 5X007</li> <li>● 5X008</li> </ul>  | <b>Accepted addition</b> of codes 5X006, 5X007, 5X008 to report thermal ultrasound tissue ablation   | January 2025   |

| Tab # | Name   | Code #   | Request-Description  | Effective Date  |
|-------|--|--|--|---|
| 14    | Coronary Therapeutic Service Revisions                     | -----  | <b>POSTPONED</b>   |   |
| 15    | Skin Cell Suspension Autograft                             | -----  | <b>POSTPONED</b>   |   |
| 16    | Hand Repair Service Bundling                               | <ul style="list-style-type: none"> <li>● 2X005</li> <li>▲ 25447</li> </ul>   | <b>Accepted addition</b> of code 2X005 to report suspension with interposition when performed; and revision of code 25447 by removing the term “interposition” and adding the phrase “interposition (eg, tendon)”  | January 2025  |
| 17    | Acetylcholine Receptor and Muscle Specific Kinase Antibody | <ul style="list-style-type: none"> <li>● 8X036</li> <li>● 8X037</li> <li>● 8X038</li> <li>● 8X039</li> </ul>   | <b>Accepted addition</b> of codes 8X036, 8X037, 8X038 to identify testing for Acetylcholine receptor (AChR) antibodies; and addition of code 8X039 to identify testing for Muscle specific kinase (MuSK) antibody  | January 2024  |
| 18    | Cat III-Digital Pathology                                  | <ul style="list-style-type: none"> <li style="width: 50%;">● X139T</li> <li style="width: 50%;">● X154T</li> <li style="width: 50%;">● X140T</li> <li style="width: 50%;">● X155T</li> <li style="width: 50%;">● X141T</li> <li style="width: 50%;">● X156T</li> <li style="width: 50%;">● X142T</li> <li style="width: 50%;">● X157T</li> <li style="width: 50%;">● X143T</li> <li style="width: 50%;">● X158T</li> <li style="width: 50%;">● X144T</li> <li style="width: 50%;">● X159T</li> <li style="width: 50%;">● X145T</li> <li style="width: 50%;">● X160T</li> <li style="width: 50%;">● X146T</li> <li style="width: 50%;">● X161T</li> <li style="width: 50%;">● X147T</li> <li style="width: 50%;">● X162T</li> <li style="width: 50%;">● X148T</li> <li style="width: 50%;">● X163T</li> <li style="width: 50%;">● X149T</li> <li style="width: 50%;">● X164T</li> <li style="width: 50%;">● X150T</li> <li style="width: 50%;">● X165T</li> <li style="width: 50%;">● X151T</li> <li style="width: 50%;">● X166T</li> <li style="width: 50%;">● X152T</li> <li style="width: 50%;">● X167T</li> <li style="width: 50%;">● X153T</li> <li style="width: 50%;">● X168T</li> </ul> | <b>Accepted addition</b> of 30 codes (X139T- X168T) to report additional service requirements associated with digitizing glass microscope slides for primary diagnosis; and revision of the Category III Digital Pathology Digitization Procedure guidelines | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |



# CPT® Editorial Summary of Panel Actions

## May 2023

| Tab # | Name   | Code #  | Request-Description   | Effective Date  |
|-------|--|---------|---|---|
| 19    | MAAA - Colon Cancer-Revise 81528                 | -----   | <b>REJECTED</b>   |   |
| 20    | Tier 1-OGM-Constitutional Genome-wide Analysis   | -----   | <b>WITHDRAWN</b>  |   |
| 21    | Tier 1-OGM- Hematologic Malignancy               | -----   | <b>WITHDRAWN</b>  |   |
| 22    | Gadolinium Serum Level                           | -----   | <b>REJECTED</b>   |   |
| 23    | Hepatitis D (Delta) Quantitative PCR             | ● 8X041 | <b>Accepted addition</b> of code 8X041 to identify quantitative detection of Hep D RNA in serum for Hep D virus confirmation  | January 2024  |
| 24    | Admin MAAA-Cardiovascular Disease                | ● 00X6M | <b>Accepted addition</b> of administrative MAAA code 00X6M to identify residual cardiovascular risk (RCVR) using a multianalyte assay with algorithm  | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 25    | GSP-Matched Normal Sequence Analysis Add-on Code | -----   | <b>WITHDRAWN</b>  |   |
| 26    | Molecular Microbial Resistance                   | -----   | <b>WITHDRAWN</b>  |   |
| 27    | Ultrasensitive Protein                           | -----   | <b>WITHDRAWN</b>  |   |
| 28    | Q2 PLA Consent Agenda                            | -----   | <b>Accepted addition</b> of 18 proprietary laboratory analyses (PLA) codes; <b>revision</b> of 7 codes (0269U, 0271U, 0272U, 0274U 0277U, 0278U, 0362U); and deletion of 4 codes (0066U, 0357U, 0386U, 0397U) | Release Date: July 1, 2023<br>Effective Date: October 1, 2023 |

Updated June 1, 2023

- New
- ▲ Revision
- ⊕ Add on
- ◻ Deletion



# CPT® Editorial Summary of Panel Actions

## May 2023

| Tab # | Name   | Code #             | Request-Description  | Effective Date   |
|-------|--|--------------------|--|--|
| 29    | Psychotherapy Codes - Revise 90832, 90834, 90837 | -----              | <b>WITHDRAWN</b>   |  |
| 30    | Adaptive Behavior Service Revisions              | -----              | <b>WITHDRAWN</b>   |  |
| 31    | Digital Cognitive Behavioral Therapy             | -----              | <b>WITHDRAWN</b>   |  |
| 32    | Psychotherapy Duration Codes                     | -----              | <b>REJECTED</b>  |  |
| 33    | mRNA RSV Vaccine                                 | ● 9X097            | Accepted addition of code 9X097 to report vaccine product, mRNA lipid nanoparticles, for intramuscular use   | Release Date: July 1, 2023<br>Effective Date: January 1, 2024        |
| 34    | Pediatric Healthy Weight Program                 |                    | <b>POSTPONED</b>   |  |
| 35    | Prolonged Psychotherapy Services                 | -----              | <b>WITHDRAWN</b>   |  |
| 36    | Respiratory Syncytial Virus, Pediatric, Seasonal | ● 9X094<br>● 9X095 | <b>Accepted addition</b> of codes 9X094, 9X095 to report use of immune globulin for pediatric protection against respiratory syncytial virus (RSV) | Release Date: Upon FDA approval<br>Effective Date: Upon FDA approval |
| 37    | HIPEC Guideline Revisions                        | -----              | <b>Accepted addition</b> of introductory guidelines that describe work that is included in the HIPEC procedures                                    | January 2024   |

Updated June 1, 2023

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

| Tab # | Name  | Code #  | Request-Description   | Effective Date |
|-------|---|---|---|----------------|
| 38    | Transcranial Doppler  | <ul style="list-style-type: none"> <li>● +93X94</li> <li>● +93X95</li> <li>● +93X96</li> <li>▲ 93893</li> <li>D93890</li> </ul> | <b>Accepted addition</b> of add-on codes to report procedures performed with complete transcranial Doppler study of intracranial arteries: vasoreactivity study (93X94), emboli detection without intravenous microbubble injection (93X95), and venous-arterial shunt detection with intravenous microbubble injection (93X96); <b>revision</b> of code 93893 to describe venous-arterial shunt detection; and <b>deletion</b> of code 93890 | January 2025   |
| 39    | Cat III - Noninvasive Artificial Intelligence Classifier      | -----   | <b>WITHDRAWN</b>  |                |
| 40    | Cat III - Hybrid SI Joint Fusion - Delete 0809T               | D0809T  | <b>Accepted deletion</b> of code 0809T and provide alternative instruction for reporting hybrid SI joint fusion   | January 2024   |
| 41    | Cat III-Cerebral Perfusion Analysis                           | -----   | <b>TERMINATED</b>   |                |
| 42    | Cat III - Percutaneous Nerve Field Stimulation - Revise 0720T | -----   | <b>WITHDRAWN</b>  |                |
| 43    | Cat III - Spectroscopy Study-Wound or Flap - Revise 0640T     | <ul style="list-style-type: none"> <li>● 0194T</li> <li>▲ 0640T</li> <li>D0641T</li> <li>D0642T</li> </ul>                      | <b>Accepted addition</b> of code 0194T to report noncontact near-infrared spectroscopy measurement, other than for screening for peripheral artery disease; <b>revision</b> of code 0640T by removing “of flap or wound” and adding “each site and/or extremity”; and <b>deletion</b> of codes 0641T, 0642T   | January 2024   |
| 44    | Cat III 0042T to Cat I - Computed Tomography Perfusion        | -----   | <b>WITHDRAWN</b>  |                |



# CPT® Editorial Summary of Panel Actions

## May 2023

| Tab # | Name   | Code #             | Request-Description  | Effective Date  |
|-------|--|--------------------|--|---|
| 45    | Cat III - Opto-Acoustic Imaging for Breast Masses  | ● +X183T           | <b>Accepted addition</b> of add-on code X183T to report opto-acoustic imaging for breast masses  | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 46    | Cat III - Vascular Embolization with Pressure Modulated Drug Delivery                                    | -----              | <b>WITHDRAWN</b>   |   |
| 47    | Cat III - Percutaneous Coronary Intervention (PCI) by Therapeutic Drug Delivery with Drug-coated Balloon | -----              | <b>WITHDRAWN</b>   |   |
| 48    | Cat III - Electrophysiological Focused Magnetic Stimulation of Brain                                     | ● X169T            | <b>Accepted addition</b> of code X169T and guidelines to report electrophysiologic-focused magnetic subthreshold and low-frequency stimulation measuring brain physiology          | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 49    | Cat III - Quantitative MRI Analysis of Brain with Comparison   | ● X188T<br>● X189T | <b>Accepted addition</b> of codes X188T, X189T to report quantitative magnetic resonance image analysis of the brain   | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 50    | Cat III - Near Infrared Spectroscopy (NIRS) for Peripheral Arterial Disease (PAD)                        | ● X171T            | <b>Accepted addition</b> of code X171T to report noncontact near-infrared spectroscopy measurement, for screening for peripheral arterial disease, including provocative maneuvers | January 2024  |
| 51    | Cat III - Capture and Harvest of Circulating Tumor Cells   | -----              | <b>REJECTED</b>  |   |
| 52    | Cat III - Prescription Digital Therapeutics  | -----              | <b>POSTPONED</b>   |   |
| 53    | Cat III - Noninvasive Pulmonary Gas Exchange Assessment  | -----              | <b>POSTPONED</b>   |   |

Updated June 1, 2023

- New
- ▲ Revision
- + Add on
- D Deletion



# CPT® Editorial Summary of Panel Actions

## May 2023

| Tab # | Name  | Code #   | Request-Description  | Effective Date  |
|-------|---|--|--|---|
| 54    | Cat III - Peripheral Nerve Transcutaneous Magnetic Stimulation            | ▲0766T<br>▲0767T<br>D0768T<br>D0769T                         | <b>Accepted revision</b> of codes 0766T, 0767T to include each treatment for peripheral nerve transcutaneous magnetic stimulation; and deletion of codes 0768T, 0769T              | January 2024  |
| 55    | Cat III - Wireless Cardiac Stimulation System for Left Ventricular Pacing | ● X180T ▲0517T<br>● X181T ▲0518T<br>● X182T ▲0519T<br>▲0520T | <b>Accepted addition</b> of codes X180T, X181T, X182T and revision of codes 0517T - 0520T to allow more granular reporting of wireless cardiac stimulator components for LV pacing | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 56    | Cat III - Low Intensity ESWT-Corpus Caverosum                             | ●X170T   | <b>Accepted addition</b> of code X170T to report low intensity extracorporeal low energy shock wave therapy involving the corpus cavernosum  | Release Date: July 1, 2023<br>Effective Date: January 1, 2024 |
| 57    | Cat III – Myofascial Pain Syndrome with Trigger Points                    | -----  | <b>WITHDRAWN</b>   |   |
| 58    | Category III Sundown  | R0512T<br>R0513T<br>D0533T<br>D0534T<br>D0535T<br>D0536T     | <b>Accepted retention</b> of Category III codes 0512T, 0513T; and deletion of Category III codes 0533T, 0534T, 0535T, 0536T that are scheduled for sundown in January 2024         | January 2024  |
| 59    | Code Set Maintenance  | R34510<br>D74710   | <b>Accepted retention</b> of code 34510; and deletion of code 74710 due to low utilization   | January 2024  |
| 60    | Appendix S AI Taxonomy Revisions  | -----  | <b>Accepted revision</b> of Appendix S-AI Taxonomy to include new examples recently included in the CPT code set that are assistive and augmentative services                      | January 2024  |
| 61    | Vaccine Early Release Policy Revision                                     | -----  | Accepted revision of the policy for  | Release Date: July 1, 2023<br>Effective Date: July 1, 2023    |

Updated June 1, 2023

- New
- ▲ Revision
- ⊕ Add on
- D Deletion





# CPT® Editorial Summary of Panel Actions

## May 2023

| Tab # | Name   | Code # | Request-Description   | Effective Date   |
|-------|--|--------|---|--|
|       |  |        | 1) Expedited release for immunizations (ie, vaccines/toxoids, immune globulins, serum or recombinant products) that meet code criteria and process for expedited release;<br>2) Revision of the FDA approval pending policy to include both vaccines and immune globulins |  |
| 62    | Delete 81439   | -----  | <b>TERMINATED</b>   |  |
| 63    | CCA Revisions Related to Digital Medicine/AI   | -----  | <b>Accepted addition</b> of questions regarding Artificial Intelligence to the CPT Code Change Application  | N/A  |
| EC    | 9X096 RSV Vaccine – Expedited Release Request  | -----  | <b>Accepted</b> early release of code 90679 to report vaccination for older adults against respiratory syncytial virus (RSV) using adjuvanted product   | Release Date: May 3, 2023<br>Effective Date: May 3, 2023 |
| EC    | RUC Report - April 2023-Issue #2<br>Tab 8 - Laser Treatment – Skin (96920, 96921, 96922)   | -----  | <b>Accepted</b> editorial revision of codes 96920-96922 to include the term, “Excimer” in the descriptors to align with intended use  | January 2024   |
| EC    | RUC Report – April 2023-Issue #3<br>Tab 6 - Telemedicine Evaluation and Management Services (9X075, 9X076, 9X077, 9X078, 9X079, 9X080, 9X081, 9X082, 9X083, 9X084, 9X085, 9X086, 9X087, 9X088, 9X089, 9X090) | -----  | <b>Accepted</b> RUC provided time recommendations for Telemedicine Evaluation and Management Services codes 9X075, 9X076, 9X077, 9X078, 9X079, 9X080, 9X081, 9X082, 9X083, 9X084, 9X085, 9X086, 9X087, 9X088, 9X089, 9X090  | January 2025   |